Report
Lilly’s GLP-1 pill Foundayo eased sleep apnea in two late-stage studies, STAT reports
Foundayo appeared less effective than Lilly’s injectable Zepbound, according to STAT’s report on the trial results.
TLDR
STAT reports that in a one-year trial among patients not using PAP breathing support, Foundayo reduced breathing disruptions by 17.8 per hour, versus 4.5 with placebo. Remission or mild disease occurred in 28% of treated patients, versus 13% on placebo. Lilly plans to seek FDA approval for obstructive sleep apnea treatment in adults with obesity or overweight by year’s end, according to Scientific American.
Combined views
—
8 Sources, first seen ago
